Levetiracetam
- Generic Name
- Levetiracetam
- Brand Names
- Elepsia, Keppra, Matever, Roweepra, Spritam, Levetiracetam Accord, Levetiracetam Teva, Levetiracetam Actavis, Levetiracetam ratiopharm, Levetiracetam Sun, Levetiracetam Actavis Group, Levetiracetam Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O2
- CAS Number
- 102767-28-2
- Unique Ingredient Identifier
- 44YRR34555
- Background
Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). Levetiracetam possesses a wide therapeutic index and little-to-no potential t...
- Indication
Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seiz...
- Associated Conditions
- Epilepsies, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Myoclonic seizures
- Associated Therapies
- -
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
- Conditions
- Interventions
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- Emory University
- Target Recruit Count
- 72
- Registration Number
- NCT01891890
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Therapy for Children With Advanced Stage Neuroblastoma
- Conditions
- Interventions
- Drug: cyclophosphamideDrug: topotecanBiological: hu14.18K322AProcedure: peripheral blood stem cell harvestProcedure: surgical resectionDrug: cisplatinDrug: etoposideDrug: doxorubicinDrug: vincristineDrug: busulfanDrug: melphalanBiological: peripheral blood stem cell transplantationBiological: natural killer cell infusionRadiation: radiation therapyBiological: GM-CSFBiological: G-CSFDrug: mesnaDrug: levetiracetamBiological: interleukin-2Drug: IsotretinoinDevice: CliniMACS
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 153
- Registration Number
- NCT01857934
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Seizure Prophylaxis in Aneurysm Repair
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 82
- Registration Number
- NCT01801072
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 7
- Registration Number
- NCT01660672
- Locations
- 🇲🇼
Queen Elizabeth Central Hospital, Blantyre, Malawi
An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01618903
- Locations
- 🇨🇳
1, Shanghai, China
A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01618877
- Locations
- 🇨🇳
1, Shanghai, China
Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children
- Conditions
- Interventions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 108
- Registration Number
- NCT01521130
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Korea UCB Co., Ltd.
- Target Recruit Count
- 353
- Registration Number
- NCT01498822
- Locations
- 🇰🇷
05, Busan, Korea, Republic of
🇰🇷10, Busan, Korea, Republic of
🇰🇷16, Busan, Korea, Republic of
Efficacy of Keppra for Neonatal Seizures
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- Stephanie Merhar, MD
- Target Recruit Count
- 2
- Registration Number
- NCT01475656
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
T-Cell Depleted Double UCB for Refractory AML
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 3
- Registration Number
- NCT01464359
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.